Moleculin reports 43% complete remission rate in Annamycin arm of Phase 2/3 AML trial

PUBT · 1d ago
Moleculin reports 43% complete remission rate in Annamycin arm of Phase 2/3 AML trial
  • Moleculin Biotech will present interim Annamycin trial results at the ASH annual meeting in New Orleans, Dec. 12-15, 2026.
  • The pivotal Phase 2/3 study found higher complete remission rates with Annamycin plus cytarabine than placebo in relapsed or refractory acute myeloid leukemia.
  • No signs of cardiotoxicity were observed through the data cutoff; independent cardiac safety reviews are planned at the second interim analysis.
  • An independent monitoring committee recommended continuing the trial without changes, retaining all three treatment arms.
  • The second interim analysis is expected in early 2027; a successful trial could support a New Drug Application submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041100PRIMZONEFULLFEED9869776) on November 04, 2026, and is solely responsible for the information contained therein.